Rhelion Life Sciences' subsidiary Filament Health has signed a letter of intent with Darmiyan to explore using Darmiyan's FDA-authorized AI brain imaging platform, BrainSee, in clinical trials for Rhelion's psilocybin drug candidate PEX010. BrainSee predicts Alzheimer's progression risk, potentially improving patient selection and trial efficiency. This collaboration aims to reduce trial size and duration while enhancing the detection of treatment effects in early cognitive impairment. The partnership highlights the innovative use of AI and psychedelics in Alzheimer's research, with plans to further develop clinical studies.
A previously inactive cryptocurrency wallet sold 37.725 million ENA tokens through BitGo for about $9.25 million. Despite this large sale, the wallet still retains a significant balance of approximately 119.82 million ENA tokens, valued at around $29...
The Helium (HNT) cryptocurrency token experienced a price decline of approximately 10% from October 4 to October 5, with prices falling from around $0.59 to about $0.53. Multiple data sources reported similar drops, but there was no uniform closing t...
Helium (HNT) gained 10% early in the day but its further rise depends on holding a key support zone. If it holds, HNT could climb to $0.64, a 16% increase. However, weakening bullish indicators and negative selling pressure suggest a possible drop to...
LayerZero (ZRO) surged 10.55% to $2.12 on October 6, 2026, despite on-chain data showing persistent inflows to centralized exchanges and an 83% wash-trading ratio, suggesting much of the volume may be artificially inflated. Over the past nine days, Z...
Grayscale's Hyperliquid Staking ETF has appointed BitGo Bank & Trust as a second custodian for some of its Hyperliquid (HYPE) assets, alongside its primary custodian Anchorage Digital Bank. The new custody agreement, effective from September 30 and d...
